Cardiac Magnetic Resonance Imaging and Clinical Follow-up in Antimalarial-induced Cardiomyopathy in Patients With Systemic Lupus Erythematosus.
Humans
Antimalarials
/ adverse effects
Stroke Volume
Ventricular Function, Left
Contrast Media
/ adverse effects
Follow-Up Studies
Magnetic Resonance Imaging, Cine
Gadolinium
Cardiomyopathies
/ chemically induced
Magnetic Resonance Imaging
Lupus Erythematosus, Systemic
/ complications
Predictive Value of Tests
Journal
Journal of thoracic imaging
ISSN: 1536-0237
Titre abrégé: J Thorac Imaging
Pays: United States
ID NLM: 8606160
Informations de publication
Date de publication:
01 May 2023
01 May 2023
Historique:
medline:
1
5
2023
pubmed:
3
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
Antimalarial-induced cardiomyopathy is under-recognized in clinical practice and there is limited data on the evolution of cardiac imaging abnormalities after cessation of anti-malarial therapy. In this case series of 9 patients with antimalarial-induced cardiomyopathy, follow-up cardiac magnetic resonance imaging demonstrated interval increase in late gadolinium enhancement extent in 89% of patients and interval decrease in left ventricular ejection fraction in all, despite cessation of anti-malarial therapy. Progression of cardiac abnormalities despite cessation of therapy underscores the important role of imaging in the early recognition of antimalarial-related treatment changes.
Identifiants
pubmed: 36728467
doi: 10.1097/RTI.0000000000000694
pii: 00005382-202305000-00010
doi:
Substances chimiques
Antimalarials
0
Contrast Media
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
W30-W32Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
K.H. has received a speaker’s honorarium from Sanofi-Genzyme, Amicus, and Medscape. P.T. has received speaker’s honorarium from Amgen, BI, and Takeda. The remaining authors declare no conflicts of interest.
Références
Tselios K, Deeb M, Gladman DD, et al. Antimalarial-induced cardiomyopathy: a systematic review of the literature. Lupus. 2018;27:591–599.
Hanneman K, Alberdi HV, Karur GR, et al. Antimalarial-induced cardiomyopathy resembles fabry disease on cardiac MRI. JACC Cardiovasc Imaging. 2020;13:879–881.
Michaelides M, Stover NB, Francis PJ, et al. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol. 2011;129:30–39.
Tett SE. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet. 1993;25:392–407.
Mackenzie AH. Pharmacologic actions of 4-aminoquinoline compounds. Am J Med. 1983;75:5–10.
Frustaci A, Morgante E, Antuzzi D, et al. Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy. Int J Cardiol. 2012;157:117–9.
Hanneman K, Karur GR, Wasim S, et al. Left ventricular hypertrophy and late gadolinium enhancement at cardiac MRI are associated with adverse cardiac events in fabry disease. Radiology. 2020;294:42–49.